Last reviewed · How we verify

NCT05449171

High Molecular Weight Hyaluronic Acid, α-lipoic Acid, Magnesium, Vitamin B6 and Vitamin D, in the Prevention of Spontaneous Abortion

Completed NA Last updated 22 February 2024
What this trial tests

NA trial testing high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D in Abortion, Spontaneous in 100 participants. Completed in 31 January 2024.

Timeline
1 September 2022
Primary endpoint
1 September 2023
31 January 2024

Quick facts

Lead sponsorLo.Li.Pharma s.r.l
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment100
Start date1 September 2022
Primary completion1 September 2023
Estimated completion31 January 2024
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Lo.Li.Pharma s.r.l

Who can join

Adults 18 to 45, female only, with Abortion, Spontaneous. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to verify if the association of high molecular weight hyaluronic acid, α-lipoic acid (ALA), magnesium, vitamin B6 and vitamin D, reduces the risk of miscarriage in patients at risk.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Abortion, Spontaneous

Currently open trials in the same condition.

Other Lo.Li.Pharma s.r.l trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05449171.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing